GlassScriptPhysician profile
Michelle J Mccarthy
NPI 1235162074
$6,550.29
in general payments reported to CMS, 2019-2025
50 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,785 · 2020: $1,757 · 2021: $2,538 · 2022: $450 · 2023: $19.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $694.63 | 2019-2022 | |
| Abbvie INC. | $587.76 | 2021-2023 | |
| Amgen INC. | $541.09 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $519.21 | 2019-2022 | |
| Lilly USA, LLC | $392.47 | 2019-2022 | |
| Pfizer INC. | $391.44 | 2019-2021 | |
| Astellas Pharma US INC | $382.20 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $276.99 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $271.16 | 2019-2022 | |
| Allergan, INC. | $234.28 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.32 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $197.70 | 2019-2021 | |
| Glaxosmithkline, LLC. | $191.29 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $144.34 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $113.10 | 2019-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.